Home Depot kicked off this week's string of retailer earnings reports. Novo Nordisk provided two major updates on its ...

Wegovy is now positioned as the first and only GLP-1 treatment.

As Eli Lilly and Novo Nordisk have been battling it out to gain market share of the growing GLP-1 weight loss market, one ...

Novo Nordisk revealed on Monday that US patients can now receive a month’s supply of Ozempic, a highly effective diabetes ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...

(CNN) - Patients in the United States can now get the popular diabetes and weight loss drug Ozempic for half the price. Novo ...

The initiative aims to identify and support new ideas for innovative oral formulations for peptide drugs such as GLP-1 ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

Novo Nordisk and Eli Lilly (NYSE:LLY) shares edged higher Tuesday following results from Viking Therapeutics’ Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment.

Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street ...

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

GoodRx (GDRX) stock is skyrocketing after the company struck a deal with Novo Nordisk (NVO) to offer lower prices on GLP-1 ...